Forest Laboratories, Inc. Announces Health Canada Approval of BYSTOLIC for the Treatment of Hypertension

  Forest Laboratories, Inc. Announces Health Canada Approval of BYSTOLIC for
  the Treatment of Hypertension

Business Wire

NEW YORK -- January 17, 2013

Forest Laboratories, Inc. (NYSE:FRX) announced today that its Canadian
subsidiary, Forest Laboratories Canada Inc. has received a Notice of
Compliance from Health Canada for BYSTOLIC® (nebivolol) tablets, a once daily
beta blocker for the treatment of hypertension.

“We are pleased that Health Canada has granted approval for BYSTOLIC. This is
an important milestone for Forest, as it is the first product approved for our
newly established Canadian subsidiary. We look forward to bringing additional
innovative Forest products to the Canadian market,” commented David Solomon,
Senior Vice President of Corporate Development and Strategic Planning, Forest
Laboratories, Inc.

BYSTOLIC is expected to be available to Canadian patients in Q2 2013.

Forest Laboratories Canada Inc. operations are based in Toronto, Ontario. To
learn more, visit

About Forest Laboratories, Inc.

Forest Laboratories' (NYSE: FRX) longstanding global partnerships and track
record developing and marketing pharmaceutical products in the United States
have yielded its well-established central nervous system and cardiovascular
franchises and innovations in anti-infective, respiratory, gastrointestinal
and pain management medicine. Forest’s pipeline, the most robust in its
history, includes product candidates in all stages of development across a
wide range of therapeutic areas. The Company is headquartered in New York, NY.
To learn more, visit

Except for the historical information contained herein, this release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve a number of risks and
uncertainties, including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
any subsequent SEC filings. Forest assumes no obligation to update
forward-looking statements contained in this release to reflect new
information or future events or developments.


Forest Laboratories, Inc.
Frank J. Murdolo, 212-224-6714
Vice President - Investor Relations
Press spacebar to pause and continue. Press esc to stop.